Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies.
Tag Archive for: antibodies
Essential Pharma has acquired Renaissance Pharma Ltd to commercialise the company’s Phase II program Hu14.18K322A in pedriatric high-risk neuroblastoma.
Genmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline with next-generation antibody-drug conjugate therapies where the company has already an inlicensing deal with former Synaffix´s ADC technology platform (which was acquired mid of 2023 by Lonza).
AVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.
Antibody engineering?The development of therapeutic antibodies is a time and cost intensive process. Biological and physicochemical properties of the lead molecules influence almost every step in the development. Investing into antibody engineering and lead optimisation during early development pays off in later steps and does not only accelerate the programme, but also increases the chance of success.
Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialise antibody therapies.
Chromatography methods and practical tips to simplify and reduce the costs of your processes